Huron Consulting Group Launches Clinical Trial Data Analytics and Visualization Service - Applied Clinical Trials


See our 2013 Buyers Guide Digital Edition.
Huron Consulting Group Launches Clinical Trial Data Analytics and Visualization Service

Source: Company News Release
Huron Consulting Group (NASDAQ: HURN), a leading provider of business consulting services, today announced the launch of its trialRxtm service, a Huron Life Sciences clinical trial data monitoring service that helps pharmaceutical, biotechnology, and medical device companies understand and mitigate clinical trial disclosure risks.

Huron Life Sciences’ trialRx service is enabled by a unique, proprietary data analytics and visualization tool that leverages a database of the 32 million unique data points available on the National Institutes of Health’s (NIH) website, The trialRx service provides an accurate, automated way to monitor clinical trial registration and results reporting compliance, allowing companies to develop focused strategies to mitigate clinical trial disclosure risks efficiently.

“The trialRx service provides life sciences companies with a straightforward, efficient way to monitor all publicly available information posted on Based on this information, they can generate insights to inform and support various clinical operations and compliance initiatives,” said Paul J. Silver, managing director and practice leader, Huron Life Sciences. “We developed the trialRx service to further support the strategic, clinical, and regulatory compliance needs of our clients in a world where data is everywhere – and where being able to use it is critical.”

Risk Exposure and Data Quality
The trialRx service equips companies to understand their overall risk exposure on for each of their clinical trials. Huron’s clients have experienced a reduction in overall noncompliance and realized additional value by using the service to enhance data quality, create business insights and identify operations improvement opportunities. Specifically, clients have used the trialRx service to identify and remediate data quality issues including errant clinical trial sponsor listings, duplicate secondary IDs, lack of universal trial numbers and identification of non-harmonized study conditions and interventions.

“Our trialRx service fills a distinct need in the marketplace by closing the loop between what is posted by clinical trial sponsors – either manually or using trial data disclosure solutions – and what regulators require,” said BJ D’Avella, director, Huron Life Sciences. “It provides sponsors an efficient, cost-effective way to understand their evolving clinical trial portfolios and can be customized to meet our clients’ unique business and compliance needs.”

Huron’s trialRx service is compatible with existing software solutions that automate aspects of the posting of trials to and can help ensure that those postings are complete, accurate, and timely.

For more information on Huron’s trialRx service or to request a demo, visit:


blog comments powered by Disqus


As it creates a plan to implement the US biosimilar pathway, should FDA:
Borrow heavily from EMA's pathway program?
Borrow lightly from EMA's pathway program?
Create entirely its own pathway program?
Borrow heavily from EMA's pathway program?
Borrow lightly from EMA's pathway program?
Create entirely its own pathway program?
View Results
Untitled Document
Source: Company News Release,
Click here